Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,751,925 | Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof In force · Medium confidence UsedRemaining | ModernaTX, Inc. | In force | Medium confidence | ||
| US 10,072,057 | Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof In force · Low confidence | ModernaTX, Inc. | In force | Low confidence | ||
| Application 16/049,212 | Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof Abandoned Abandoned Nov 28, 2022 | ModernaTX, Inc. | Abandoned | Abandoned Nov 28, 2022 | ||
| Application 18/049,582 | Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof Abandoned Abandoned Jun 13, 2025 | ModernaTX, Inc. | Abandoned | Abandoned Jun 13, 2025 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Moderna Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.